A large number of phenotypically and genotypically distinct neurodegenerative disorders are characterized by the accumulation of proteinacious, and often fibrillar aggregates and these aggregates are the defining neuropathologic features of many neurodegenerative disorders. While frontotemporal dementia (FTD) is a relatively well-defined clinical disorder, the neuropathology of FTDs is evolving at a rapid pace and is far from well delineated at this time. Indeed, the clinically defined FTD syndromes are associated with multiple neuropathologically defined disorders, but these relationships remain ill-defined and incompletely characterized. Thus, a thorough postmortem examination of subjects with FTD is essential to further refine the clinicopathologic correlation in these patients as well as provide material for the elucidation of molecular mechanisms of disease. Thus, the growing cohort of FTD patients followed in Project 1 in this Program Project Grant (PPG) and the increasing number of postmortem brain samples in need of characterization and study in this PPG mandates inclusion of a Neuropathology Core. The Neuropathology Core supports the overall goals of this PPG by providing diagnostic neuropathology, brain and biological sample banking, database tracking of samples and neuropathology data on all frontotemporal dementia (FTD) subjects followed in Project 1 of this PPG. In addition, the Core provides advice and consultation to all PPG investigators, nearly all of whom utilize human biological samples.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG017586-10
Application #
7803662
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2009-03-01
Budget End
2010-02-28
Support Year
10
Fiscal Year
2009
Total Cost
$149,999
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Zee, Jarcy; Xie, Sharon X (2018) The Kaplan-Meier Method for Estimating and Comparing Proportions in a Randomized Controlled Trial with Dropouts. Biostat Epidemiol 2:23-33
Oukoloff, Killian; Kovalevich, Jane; Cornec, Anne-Sophie et al. (2018) Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. Bioorg Med Chem Lett 28:2180-2183
Phillips, Jeffrey S; Das, Sandhitsu R; McMillan, Corey T et al. (2018) Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp 39:691-708
Smith, Kara M; Ash, Sharon; Xie, Sharon X et al. (2018) Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. J Speech Lang Hear Res 61:1691-1699
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Lee, Edward B (2018) Integrated neurodegenerative disease autopsy diagnosis. Acta Neuropathol 135:643-646
Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Rennert, Lior; Xie, Sharon X (2018) Cox regression model with doubly truncated data. Biometrics 74:725-733
Sandelius, Åsa; Portelius, Erik; Källén, Åsa et al. (2018) Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimers Dement :

Showing the most recent 10 out of 593 publications